EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials

Rahul Falodia iD, Ehsanullah Alokozay iD, Mohammad Idrees, Darsh Paghdar, Ali Msheik, Taha Alam iD, Saeedullah Zadran

Clinical Cardiology · 2026-06 · 49 (6)

DOI: 10.1002/clc.70391 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Cardiology, online erschienen am 23.06.2026. Verfasst von Rahul Falodia und 6 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, Jodhpur, India. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Baxdrostat is a selective aldosterone synthase (CYP11B2) inhibitor for treatment‐resistant and uncontrolled hypertension, evaluated in phase 2/3 RCTs.

Objectives

To estimate pooled placebo‐corrected reductions in seated office and ambulatory SBP, characterize the dose–response relationship, assess cortisol selectivity, and quantify hyperkalemia risk.

Methods

We conducted a systematic review and meta‐analysis of phase 2/3 randomized, double‐blind, placebo‐controlled trials of baxdrostat in hypertension, searching MEDLINE/PubMed, EMBASE, ClinicalTrials.gov, and NEJM.org to March 2026. The primary outcome was placebo‐corrected change in seated office SBP, analyzed using random‐effects meta‐analysis (REML) with metafor in R. Risk of bias and certainty were evaluated using Cochrane RoB 2.0 and GRADE, respectively.

Results

Three RCTs (BrigHTN, BaxHTN, Bax24; N = 1285) were included. The pooled seated SBP reduction was −9.44 mmHg (95% CI: −11.09 to −7.79; I 2 = 0.0%), with dose subgroup estimates of −8.57 mmHg (1 mg) and −10.11 mmHg (2 mg) and a clear dose–response in BrigHTN (slope −4.2 mmHg/mg; R 2 = 0.96). Bax24 demonstrated a 24 h ambulatory SBP reduction of −14.0 mmHg (95% CI: −17.2 to −10.8). Serum cortisol was unsuppressed at all doses, while the pooled OR for potassium ≥ 6.0 mmol/L was 5.14 (95% CI: 1.76 to 14.97). GRADE certainty was moderate for seated SBP, low to moderate for ambulatory outcomes, and low for hyperkalemia.

Conclusions

Baxdrostat produces meaningful, selective BP reductions across hypertensive populations. Hyperkalemia is manageable with structured monitoring. Certainty is limited by a few trials, a short follow‐up, and safety imprecision. Long‐term cardiovascular outcome data are needed before guideline incorporation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionAntihypertensive AgentsBlood PressureHumansRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicClinical Trials, Phase II as TopicTreatment Outcome

Stichwörter der Autor:innen

CYP11B2aldosterone synthase inhibitorambulatory blood pressurebaxdrostathyperkalemiameta‐analysisresistant hypertensionsystematic review

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • All India Institute of Medical Sciences, Jodhpur, India.
  • Faculty of Medicine, Kandahar University, Kandahar, Afghanistan.
  • Saidu Medical College, Saidu Sharif, Swat, Pakistan.
  • Neurosurgery Department, Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar.
  • Dow University of Health Sciences, Karachi, Pakistan.
  • White River Medical Center, Batesville, Arkansas, USA.

ORCID-Profile: Rahul Falodia, Ehsanullah Alokozay, Taha Alam

Zitieren

APA

Falodia, R., Alokozay, E., Idrees, M., Paghdar, D., Msheik, A., Alam, T., & Zadran, S. (2026). Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials. Clinical Cardiology, 49(6). https://doi.org/10.1002/clc.70391

Vancouver

Falodia R, Alokozay E, Idrees M, Paghdar D, Msheik A, Alam T, et al. Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials. Clinical Cardiology. 2026;49(6). doi:10.1002/clc.70391

BibTeX
@article{Falodia2026,
  author = {Falodia, Rahul and Alokozay, Ehsanullah and Idrees, Mohammad and Paghdar, Darsh and Msheik, Ali and Alam, Taha and Zadran, Saeedullah},
  title = {Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials},
  journal = {Clinical Cardiology},
  year = {2026},
  volume = {49},
  number = {6},
  doi = {10.1002/clc.70391}
}
Kostenlos starten →